UPTEMPO
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

UPTEMPO Trademark

Serial Number: 97921045

UPTEMPO is a trademark filed by CATALENT PHARMA SOLUTIONS, INC. on May 4, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

CATALENT PHARMA SOLUTIONS, INC. (64 trademarks)

14 Schoolhouse Road
Somerset, NJ 08873

Entity Type: 03

Trademark Details

Filing Date

May 4, 2023

Registration Date

Not Registered

Published for Opposition

January 23, 2024

Goods & Services

Cells and cell lines for scientific, laboratory or medical research; Reagents for scientific or medical research use; Biological and biochemical preparations, namely, plasmids, RNA and proteins for scientific, medical research, or research use; Cell culture reagents for scientific and research use; Stem cells for research or scientific purposes; Biological preparations for use in cell cultures other than for medical or veterinary use; Engineered proteins for use in scientific research and analysis relating to genetic diseases, gene therapy, and cell therapy; biochemicals and biologics, namely, engineered nucleic acids, viral vectors, non-viral vectors, gene therapy vectors, gene editing vectors, genetically modified cells, engineered proteins for multiplexed gene editing, mRNA and recombinant adeno-associated virus (AAV) vectors for delivery of therapeutic DNA or mRNA sequences to cells, antibody preparations, chimeric antigen receptor (CAR) T-cell preparations, T-cell preparations, tumor-infiltration lymphocyte (TIL) preparations, natural killer (NK) cell preparations, induced pluripotent stem cell (iPSC) preparations, mesenchymal stem cell (MSC) preparations, all for use in scientific research and analysis

Pharmaceutical research and development; Gene therapy research; Cell therapy research; Scientific research

Cells and cell lines for medical or clinical use; Stem cells for medical or veterinary use; Engineered proteins for use in scientific research and analysis relating to genetic diseases, gene therapy, and cell therapy; biochemicals and biologics, namely, engineered nucleic acids, viral vectors, non-viral vectors, gene therapy vectors, gene editing vectors, DNA plasmids, genetically modified cells, engineered proteins for multiplexed gene editing, mRNA and recombinant adeno-associated virus (AAV) vectors for delivery of therapeutic DNA or mRNA sequences to cells, antibody preparations, chimeric antigen receptor (CAR) T-cell preparations, T-cell preparations, tumor-infiltration lymphocyte (TIL) preparations, natural killer (NK) cell preparations, induced pluripotent stem cell (iPSC) preparations, mesenchymal stem cell (MSC) preparations, all for clinical use, medical use, clinical laboratory use, and medical laboratory use; Pharmaceutical preparations in the nature of viral systems, gene therapy systems, and nucleic acid delivery systems comprised of viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells used to deliver modified genetic material into other cells for medical purposes

Custom manufacture of cells and cell lines for use in viral vector production, and for diagnostic, medical and commercial applications in relation to cell and gene therapies

Filing History

SOU TEAS EXTENSION RECEIVED
May 14, 2026 EEXT
TEAS STATEMENT OF USE RECEIVED
Jan 21, 2026 EISU
TEAS REQUEST TO DIVIDE RECEIVED
Jan 21, 2026 ERTD
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 10, 2025 EXRA
SOU EXTENSION 3 GRANTED
Nov 10, 2025 EX3G
SOU EXTENSION 3 FILED
Nov 10, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Nov 10, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 15, 2025 EXRA
SOU EXTENSION 2 GRANTED
May 14, 2025 EX2G
SOU EXTENSION 2 FILED
May 14, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
May 14, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 27, 2024 EXRA
SOU EXTENSION 1 GRANTED
Sep 27, 2024 EX1G
SOU EXTENSION 1 FILED
Sep 27, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Sep 27, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
May 14, 2024 NOAM
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Apr 3, 2024 ETOP
EXTENSION OF TIME TO OPPOSE RECEIVED
Feb 13, 2024 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 23, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jan 23, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 3, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 21, 2023 CNSA
ASSIGNED TO EXAMINER
Dec 20, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 4, 2023 NWOS
NEW APPLICATION ENTERED
May 8, 2023 NWAP